Skip to content

Addiction: all studies

Page 342 of 860: studies 3,411 to 3,420 of 8,594, newest first. Back to the addiction overview

Research

Nurses' Perceptions of Psychedelics to Address Mental Health Problems in the United States.

Psychedelic Medicine September 1, 2024 Carolyn M. Porta, Madison E. Weirick, Anna Graefe et al. 4 citations

To explore nurses' knowledge, attitudes, and perceived social norms about psychedelic use to address mental health conditions. Data were collected through an anonymous e-survey of Minnesota registered nurses, advanced practice registered nurses, and psychiatric-mental health nurse practitioners in Spring 2023; the pool was randomly selected from the Minnesota Board of Nursing registry. A total...

The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).

Journal of Affective Disorders September 1, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 8 citations

Ketamine and esketamine have been proven to be effective in treating adults with treatment resistant depression (TRD). Preliminary evidence indicates that, when combined with behavioral and psychological interventions, both agents may offer benefits for individuals with substance use disorder (SUD) and alcohol use disorder (AUD). Notwithstanding, concerns have been raised as to whether either...

DOI: 10.1016/j.jad.2024.05.116 (opens in new tab) Full text (opens in new tab) Diversion Ketamine abuse liability Treatment-resistant depression trd Adverse event reporting +2

The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials.

Psychiatry Research September 1, 2024 Jianhua Yang, Ni Wang, Wulin Luo et al. 14 citations

3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is one of the most widely used illicit substances worldwide. MDMA-assisted psychotherapy has become a novel treatment for posttraumatic stress disorder (PTSD), and many randomized controlled trials (RCTs) have been performed over the past decade. Therefore, this study aimed to systematically review and demonstrate the efficacy...

Bioisosteric analogs of MDMA: Improving the pharmacological profile?

Journal of Neurochemistry September 1, 2024 Ana Sofia Alberto-Silva, Selina Hemmer, Hailey A. Bock et al. 10 citations

3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is re-emerging in clinical settings as a candidate for the treatment of specific neuropsychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic...

DOI: 10.1111/jnc.16149 (opens in new tab) Full text (opens in new tab) Psychopharmacology Drug-development Mental-health MDMA-Research +1

Role of oxidative phosphorylation in the antidepressant effects of arketamine via the vagus nerve-dependent spleen-brain axis.

Neurobiology of Disease September 1, 2024 Lijia Chang, Yan Wei, Youge Qu et al. 22 citations

Arketamine, the (R)-enantiomer of ketamine, exhibits antidepressant-like effects in mice, though the precise molecular mechanisms remain elusive. It has been shown to reduce splenomegaly and depression-like behaviors in the chronic social defeat stress (CSDS) model of depression. This study investigated whether the spleen contributes to the antidepressant-like effects of arketamine in the CSDS...

DOI: 10.1016/j.nbd.2024.106573 (opens in new tab) Full text (opens in new tab) Arketamine Oxidative phosphorylation Spleen-brain axis Vagus nerve +5

Antagonistic interaction between caffeine and ketamine in zebrafish: Implications for aquatic toxicity.

Environmental science and ecotechnology September 1, 2024 Zhenglu Wang, Jindong Xu, Wei Du 6 citations

The coexistence of caffeine (CF) and ketamine (KET) in surface waters across Asia has been widely reported. Previous studies have implied that CF and KET may share a mechanism of action. However, the combined toxicity of these two chemicals on aquatic organisms remains unclear at environmental levels, and the underlying mechanisms are not well understood. Here we demonstrate that KET...

Psychotropic Drugs Reemerging as Headache Medicines.

CNS Drugs September 1, 2024 Emmanuelle A. D. Schindler 2 citations

Scientific and public attention on the therapeutic effects of psychedelics and other psychoactive compounds in headache disorders has recently grown. The use and reported therapeutic effects of such treatments have long been reported, though formal clinical trials are only recently taking place. When considering how these substances might be further studied and eventually applied, it is...

DOI: 10.1007/s40263-024-01107-x (opens in new tab) Full text (opens in new tab) Psychedelics Headache treatment Alternative medicine Neurological disorders +1

Potential effect of ketamine in treatment for dextromethorphan use disorder exploding in Japanese young population.

Asian Journal of Psychiatry September 1, 2024 Kaori Ishii, Kyoji Okita 1 citation

In Japan, the landscape of clinical practice for substance use disorder is changing significantly, primarily due to an increase in patients using over-the-counter drugs. A major concern is the rising number of patients misusing dextromethorphan (DXM). These patients with DXM use disorders often have severe trauma-related and mood symptoms, and therefore try to cope with those symptoms by...

DOI: 10.1016/j.ajp.2024.104164 (opens in new tab) Full text (opens in new tab) Anxiety Dextromethorphan Over-the-counter medication Self medication +11

Neurocognitive changes in a patient receiving esketamine for treatment-resistant depression.

JAAPA September 1, 2024 Carolyn F Kundert, Robert M Sobule, Muaid Ithman 1 citation

Esketamine, the s(+) enantiomer of ketamine, was approved in 2019 as the first rapid-acting intranasal spray medication for treatment-resistant depression; the drug is given in combination with an antidepressant. The treatment is self-administered in a clinical setting under the supervision of a healthcare provider and usually is well tolerated. Many of its adverse reactions are mild,...

DOI: 10.1097/01.JAA.0000000000000036 (opens in new tab) Full text (opens in new tab) Depression treatment Cognitive side effects Esketamine therapy Mental health research +1

Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice.

Journal of veterinary science September 1, 2024 Sun Mi Gu, Eunchong Hong, Sowoon Seo et al. 1 citation

Glutamic acid decarboxylase 67 (GAD67) is a gamma-aminobutyric acid (GABA) synthesis enzyme associated with the function of other neurotransmitter receptors, such as the N-methyl-D-aspartate (NMDA) receptor and cannabinoid receptor 1. However, the role of GAD67 in the development of different abused drug-induced reward behaviors remains unknown. In order to elucidate the mechanisms of substance...

DOI: 10.4142/jvs.23325 (opens in new tab) Full text (opens in new tab) Gad67 Jwh-018 Conditioned place preference Gamma-aminobutyric acid +5